Zhanel George G, Hisanaga Tamiko L, Laing Nancy M, DeCorby Melanie R, Nichol Kim A, Weshnoweski Barb, Johnson Jack, Noreddin Ayman, Low Don E, Karlowsky James A, Hoban Daryl J
Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, and Department of Medicine, Health Sciences Centre, Winnipeg, Man., Canada.
Int J Antimicrob Agents. 2006 Jun;27(6):468-75. doi: 10.1016/j.ijantimicag.2006.02.009. Epub 2006 May 18.
The North American Urinary Tract Infection Collaborative Alliance (NAUTICA) study determined the antibiotic susceptibility to commonly used agents for urinary tract infections of outpatient Escherichia coli urinary isolates obtained from various geographic regions in the USA and Canada. NAUTICA involved 40 medical centres (30 from the USA and 10 from Canada). From April 2003 to June 2004 inclusive, each centre submitted up to 50 consecutive outpatient midstream urine isolates. All isolates were identified to species level by each laboratory's existing protocol. Susceptibility testing was determined using the Clinical and Laboratory Standards Institute (CLSI) microdilution method. Ampicillin (resistant>or=32 microg/mL), sulphamethoxazole/trimethoprim (SMX/TMP) (resistant>or=4 microg/mL), nitrofurantoin (resistant>or=128 microg/mL), ciprofloxacin (resistant>or=4 microg/mL) and levofloxacin (resistant>or=8 microg/mL) resistance breakpoints used were those published by the CLSI. Of the 1142 E. coli collected, 75.5% (862) were collected from the USA and 280 (24.5%) were from Canada. Patient demographics revealed a mean age of 48.1 years (range, 2 months to 99 years), with female patients representing 79.4% of patients and males representing 20.6%. Overall, resistance to ampicillin was 37.7%, followed by SMX/TMP (21.3%), nitrofurantoin (1.1%), ciprofloxacin (5.5%) and levofloxacin (5.1%). Resistance rates for all antimicrobials were higher in US medical centres compared with Canadian centres (P<0.05). Fluoroquinolone resistance was highest in patients>or=65 years of age (P<0.05). Resistance rates demonstrated considerable geographic variability both in the USA and Canada. This study reports higher rates of antibiotic resistance in US versus Canadian outpatient urinary isolates of E. coli and demonstrates the continuing evolution of resistance to antimicrobial agents.
北美尿路感染协作联盟(NAUTICA)研究确定了从美国和加拿大不同地理区域获取的门诊大肠杆菌尿培养分离株对常用尿路感染治疗药物的抗生素敏感性。NAUTICA研究涉及40个医疗中心(30个来自美国,10个来自加拿大)。从2003年4月至2004年6月(含),每个中心提交了最多50株连续的门诊中段尿培养分离株。所有分离株均按照各实验室现有的方案鉴定到种水平。药敏试验采用临床和实验室标准协会(CLSI)微量稀释法。氨苄西林(耐药≥32μg/mL)、磺胺甲恶唑/甲氧苄啶(SMX/TMP)(耐药≥4μg/mL)、呋喃妥因(耐药≥128μg/mL)、环丙沙星(耐药≥4μg/mL)和左氧氟沙星(耐药≥8μg/mL)的耐药断点采用CLSI公布的标准。在收集的1142株大肠杆菌中,75.5%(862株)来自美国,280株(24.5%)来自加拿大。患者人口统计学数据显示,平均年龄为48.1岁(范围为2个月至99岁),女性患者占患者总数的79.4%,男性占20.6%。总体而言,对氨苄西林的耐药率为37.7%,其次是SMX/TMP(21.3%)、呋喃妥因(1.1%)、环丙沙星(5.5%)和左氧氟沙星(5.1%)。与加拿大医疗中心相比,美国医疗中心所有抗菌药物的耐药率更高(P<0.05)。65岁及以上患者的氟喹诺酮耐药率最高(P<0.05)。在美国和加拿大,耐药率均呈现出显著的地理差异。本研究报告了美国门诊大肠杆菌尿培养分离株的抗生素耐药率高于加拿大,并证明了对抗菌药物的耐药性在持续演变。